

1 **Evaluation of a Rapid and Accessible RT-qPCR Approach for SARS-CoV-2 Variant of Concern**

2 **Identification**

3

4 Priscilla S.-W. Yeung, MD, PhD^{a*}; Hannah Wang, MD^{a*}; Mamdouh Sibai, BS^a; Daniel Solis, BS^a; Fumiko
5 Yamamoto, MS^a; Naomi Iwai, CLS^b; Becky Jiang, CLS^b; Nathan Hammond, PhD^c; Bernadette Truong,
6 CLS^b; Selamawit Bihon, CLS^b; Suzette Santos, CLS^b; Marilyn Mar, CLS^b; Claire Mai, BS^c; Kenji O. Mfuh,
7 PhD^b; Jacob A. Miller, MD^d; ChunHong Huang, MD^a; Malaya K. Sahoo, PhD^a; James L. Zehnder, MD^a;
8 Benjamin A. Pinsky, MD, PhD^{a,b,e,#}

9

10 ^a Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

11 ^b Clinical Virology Laboratory, Stanford Health Care, Stanford, CA, USA

12 ^c Clinical Genomics Laboratory, Stanford Health Care, Stanford, CA, USA

13 ^d Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA

14 ^e Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University
15 School of Medicine, Stanford, CA, USA

16

17 Running Head: SARS-CoV-2 Variant of Concern Genotyping

18

19 #Address correspondence to Benjamin A. Pinsky, MD, PhD, bpinsky@stanford.edu

20

21 *Authors Priscilla S.-W. Yeung and Hannah Wang contributed equally to this work. Author order was
22 determined reverse-alphabetically.

23 **ABSTRACT**

24

25 The ability to distinguish between SARS-CoV-2 variants of concern (VOCs) is of ongoing interest due to
26 differences in transmissibility, response to vaccination, clinical prognosis, and therapy. Although detailed
27 genetic characterization requires whole-genome sequencing (WGS), targeted nucleic acid amplification
28 tests can serve a complementary role in clinical settings, as they are more rapid and accessible than
29 sequencing in most laboratories.

30

31 We designed and analytically validated a two-reaction multiplex reverse transcription quantitative PCR
32 (RT-qPCR) assay targeting spike protein mutations L452R, E484K, and N501Y in Reaction 1, and del69-
33 70, K417N, and T478K in Reaction 2. This assay had 95-100% agreement with WGS in 502 upper
34 respiratory swabs collected between April 26 and August 1, 2021, consisting of 43 Alpha, 2 Beta, 20
35 Gamma, 378 Delta, and 59 non-VOC infections. Validation in a separate group of 230 WGS-confirmed
36 Omicron variant samples collected in December 2021 and January 2022 demonstrated 100% agreement.

37

38 This RT-qPCR-based approach can be implemented in clinical laboratories already performing SARS-
39 CoV-2 nucleic acid amplification tests to assist in local epidemiological surveillance and clinical decision-
40 making.

41

42 **INTRODUCTION**

43

44 Since the original strain of SARS-CoV-2 virus was first discovered in late 2019, numerous new variants
45 have been identified, including variants of concern (VOCs) Alpha (B.1.1.7 and Q.*), Beta (B.1.351),
46 Gamma (P.1 and sublineages), Delta (B.1.617.2 and AY.*) and Omicron (B.1.1.529 and BA.*).
47 Importantly, these VOCs differ in their clinical prognosis, transmissibility, antibody susceptibility, and
48 response to vaccination (1-21). Whole-genome sequencing (WGS) has played a critical role in identifying
49 the emergence of these new variants (22-24), and millions of distinct sequences have been deposited
50 into public repositories such as the Global Initiative on Sharing Avian Influenza Data consortium's
51 database (GISAID). However, WGS has a relatively long turnaround time, is labor-intensive, and requires
52 instruments, bioinformatics support, and specially-trained staff that may not be widely available to many
53 clinical laboratories. Therefore, the development of reverse transcription quantitative PCR (RT-qPCR)
54 assays to detect and differentiate SARS-CoV-2 variants may be an important real-time complement to
55 WGS epidemiologic surveillance, and may directly impact the clinical care of individual patients by
56 informing selection of expensive and potentially difficult-to-source monoclonal antibody therapies (1, 6,
57 12-16, 19, 20, 25).

58

59 In this study, we report the design of a multiplex RT-qPCR assay that detects the del69-70, K417N, and
60 T478K mutations in SARS-CoV-2 spike protein and targets the wild-type 69-70 sequence as an internal
61 control. We further evaluate the performance of this assay in combination with our previously described
62 RT-qPCR assay for the detection of L452R, E484K, and N501Y (26), and demonstrate the utility of this
63 targeted mutational analysis to accurately distinguish among VOCs.

64 MATERIALS AND METHODS

65

66 *Assay Design*

67 The spike protein mutations associated with each variant that are interrogated by the RT-qPCR assays
68 are summarized in Figure 1. In the first reaction (Reaction 1), we utilized our previously described RT-
69 qPCR assay to detect L452R, E484K, and N501Y mutations in spike Receptor Binding Domain (RBD)
70 (26). The present study describes the combination of this assay with a second, newly designed reaction
71 (Reaction 2), which detects the deletion of amino acids 69-70 in the spike N-Terminal Domain (del69-70),
72 as well as K417N and T478K mutations in the RBD. We use allele-specific RT-qPCR with probe
73 sequences designed to maximize the difference in annealing temperature between mutant and wild-type
74 sequences, allowing for differential binding and amplification. The primer/probe sequences for each
75 mutation site are summarized in Table 1. Additional details are provided in the Supplemental Methods,
76 ssDNA sequences for analytical experiments (Supplemental Table 1), guidance for interpretation and
77 reporting (Supplemental Table 2), analytical validation data (Supplemental Table 3), and in-silico analysis
78 of primer and probe sequences (Supplemental Figure 1).

79

80 *Clinical Specimens*

81 The samples included in the initial phase of this study were upper respiratory swab specimens collected
82 from patients as part of routine clinical care from April 26, 2021 to August 1, 2021. Testing was performed
83 at Stanford Clinical Virology Laboratory, which provides virologic testing for all Stanford-affiliated hospitals
84 and outpatient centers in the San Francisco Bay Area. These initial SARS-CoV-2 nucleic acid
85 amplification tests (NAATs) tests prior to genotyping were conducted according to manufacturer and
86 emergency authorization instructions as previously described (26), and in the Supplemental Methods. All
87 samples that tested positive for SARS-CoV-2 RNA were reflexed to genotyping. We then excluded
88 samples that were initially tested by laboratory-based methods with cycle threshold values (Ct) ≥ 35 or
89 relative light units (RLU) ≤ 1100 . We included all available samples initially tested at or near the point of
90 care as Ct data was not readily available for real-time specimen triage for these samples. We also
91 excluded follow-up specimens to eliminate patient-level duplicates. Subsequent validation of this assay

92 for Omicron variant detection was conducted using a convenience set of 230 Omicron variant samples
93 with available WGS data collected between December 2, 2021 and January 5, 2022. This study was
94 conducted with Stanford institutional review board approval (protocol 57519), and individual consent was
95 waived.

96

97 *Whole-Genome Sequencing*

98 To validate the genotyping RT-qPCR reactions, we tested their performance against WGS in a subset of
99 the samples in the initial April 26, 2021 to August 1, 2021 cohort with Ct <30. Samples with non-dominant
100 variant typing by RT-qPCR were prioritized for sequencing, with the remaining isolates chosen randomly
101 to fill a sequencing run. WGS was conducted as described previously, using a lab-developed pipeline
102 consisting of long-range PCR, followed by fragmentation, then single-end 150-cycle sequencing using
103 MiSeq reagent kit V3 (Illumina, San Diego, CA) (26). Genomes were assembled via a custom assembly
104 and bioinformatics pipeline using NCBI NC_045512.2 as reference. Whole-genome sequences with ≥75%
105 genome coverage to a depth of at least 10 reads were accepted for interpretation. Median number of
106 aligned reads was 485,870 (interquartile range [IQR] 289,363-655,481), while median genome coverage
107 to a depth of at least 10 reads was 99.3% (IQR 97.1-99.3%). Mutation calling required a depth of at least
108 12 reads with a minimum variant frequency of 20%. PANGO lineage assignment was performed using
109 <https://pangolin.cog-uk.io/> running pangolin version 3.1.17, while Nextclade Web v1.13.1 and auspice.us
110 0.8.0. were used to perform phylogenetic placement (2, 27, 28). Both lineage and clade assignments
111 were performed on February 1, 2022. WGS data was deposited in GISAID (Supplemental Table 4).

112

113 *Statistical Analysis*

114 Positive percent agreement (PPA) and negative percent agreement (NPA) were reported with Clopper-
115 Pearson score 95% binomial confidence intervals (CI) using WGS as the reference method. Analyses
116 were conducted using the R statistical software package. This study was reported in accordance with
117 Standards for the Reporting of Diagnostic Accuracy Studies (STARD) guidelines.

118 **RESULTS**

119

120 During the initial study period of April 26, 2021 to August 1, 2021, the Stanford Clinical Virology
121 Laboratory received 102,158 specimens from 70,544 unique individuals. A total of 1,657 samples from
122 unique individuals tested positive for SARS-CoV-2, of which 1,093 (66%) had genotyping RT-qPCR
123 Reaction 1 and Reaction 2 performed, and 502 (30.3%) had successful WGS performed (Supplemental
124 Figure 2). Of note, Reaction 1 was performed in near real-time, while Reaction 2 was performed
125 retrospectively. Overall, this subset of sequenced samples, had patient and testing characteristics that
126 closely resembled those of the larger cohorts (Supplemental Table 5).

127

128 The assay resulted as “Unable to Genotype” in 152 of 1,093 samples (14%) due to lack of amplification of
129 any target in either or both reactions. Assay failure occurred predominantly in samples originally tested at
130 or near the point of care (119/341, 35%), where all positive samples were triaged for genotyping without
131 any filter. In contrast, assay failure occurred much less frequently in samples originally tested in the
132 moderate-to-high complexity virology lab (33/752, 4%), where samples with lower viral loads were not
133 triaged for genotyping.

134

135 For the combination of Reactions 1 and 2, the PPAs for del69-70, L452R, T478K, E484K, and N501Y
136 were 100% (Table 2). Across all six loci, only K417N had a false negative, resulting in a PPA of 96%
137 (27/28). In this sample, WGS showed a synonymous T to C mutation at position 1254 of the spike gene
138 corresponding to amino acid position 418, changing the codon from ATT to ATC. This single base pair
139 substitution likely decreased the annealing temperature, causing probe dropout and a false negative
140 result.

141

142 The NPAs for del69-70, K417N, T478K, and N501Y were 100% (Table 2). L452R had an NPA of 95%
143 (94/99) and E484K had an NPA of 99% (464/467). At the L452 locus, there were five samples positive for
144 L452R mutation by RT-qPCR that were negative by WGS. Manual review of the WGS data showed that
145 these were likely false negative WGS results due to insufficient (<12 reads) coverage at this codon. There

146 were 3-9 reads containing the L452R mutation identified in the WGS primary data in each of these five
147 samples. These five samples were all in the Delta lineage based on mutations found at other positions by
148 sequencing.

149
150 For the E484K target, there were three samples that tested positive for the E to K mutation but in fact had
151 a E484Q mutation determined by WGS. In both the E to K mutation (GAA to AAA) as well as the E to Q
152 mutation (GAA to CAA), there was a single base substitution at the first position of the codon resulting in
153 nonspecific probe binding. These three samples had a distinct blunted amplification curve with high Ct
154 values associated with E484Q, as previously described (29).

155
156 Of note, there was a subset of variant AY.2, involving four specimens in our cohort, that had a V70F
157 mutation causing both del69-70 and wt69-70 probes not to bind. However, because this variant would
158 have T478K and K417N detected, the wt69-70 signal was not needed as an amplification control. This
159 scenario has been reflected in the clinical interpretation table (Supplemental Table 2).

160
161 SARS-CoV-2 positive specimens collected starting December 2, 2021 began to show an unusual
162 combination of mutations: presence of K417N and del69-70 only in Reaction 2, with all targets including
163 internal control N501 not detected in Reaction 1. Based on in-silico analysis, we determined that these
164 cases likely represented Omicron variant. While most Omicron variant strains possess del69-70, K417N,
165 T478K, and N501Y mutations, they also have mutations at A67V, S477N, and Q498R, which would be
166 predicted to interfere with binding of the del69-70/wt69-70, T478K, and N501Y/N501 probes, respectively.
167 The del69-70 probe likely was able to retain some degree of binding due to the wider melting temperature
168 differential of a 6-nucleotide deletion compared to a point mutation. As such, we validated this assay for
169 Omicron detection using a set of 230 SARS-CoV-2 positive samples confirmed to be Omicron by WGS.
170 We found that the unique pattern of K417N and del69-70 in Reaction 2, along with failure to amplify any
171 target including internal control in Reaction 1, was present in 230/230 (100%, 95% CI 98-100%) Omicron
172 samples tested. This pattern was not seen in any of the 1,093 non-Omicron samples previously
173 genotyped.

174

175 We next predicted the WHO variant designation of samples using RT-qPCR and correlated them with the
176 PANGO lineage assignments based on WGS data (Table 3). Mapping the genotyping results of the
177 cohort based on RT-qPCR mutation analysis onto the Nextclade phylogenetic tree demonstrated close
178 correlation with their WHO variant designations (Figure 2). Among the 732 clinical samples that were
179 tested by both RT-qPCR and WGS, 43 samples (5.9%) were Alpha (B.1.1.7 or Q.3), 2 samples (0.3%)
180 were Beta (B.1.351), 20 samples (2.7%) were Gamma (P.1 and sublineages), 378 samples (51.6%) were
181 Delta (B.1.617.2 or AY.*), and 230 samples (31.4%) were Omicron (B.1.1.529 or BA.*). There were no
182 RT-qPCR false negatives in assigning samples to these lineages. In addition, there were 59 samples
183 (8.1%) tested by WGS that did not correspond to a WHO VOC as of February 2, 2022. Within this subset,
184 there were 4 samples that were erroneously assigned as Gamma and 1 that was assigned as Beta by
185 RT-qPCR. By WGS, these samples were variant of interest (VOI) Mu (B.1.621 or BB.2). This variant
186 shares mutations E484K and N501Y with both the Beta and Gamma variants. A subset of Mu also
187 includes the K417N mutation which is seen in the Beta variant. Thus, our PCR assay could not
188 distinguish VOI Mu from VOCs Beta and Gamma. Our interpretation table included in the supplementary
189 information reflects this limitation (Supplemental Table 2). The remaining 54 samples did not contain
190 mutation patterns associated with VOCs.

191

192 DISCUSSION

193

194 The ability to distinguish between SARS-CoV-2 VOCs is important for epidemiologic surveillance, and in
195 certain circumstances, the care of individual COVID-19 patients. In this study, we describe a two-reaction,
196 multiplex RT-qPCR genotyping approach that examines the spike mutations del69-70, K417N, L452R,
197 T478K, E484K, and N501Y. This targeted mutational analysis can be used to differentiate between the
198 WHO VOCs Alpha (B.1.1.7 and Q.*), Beta (B.1.351), Gamma (P.1 and sublineages), Delta (B.1.617.2
199 and AY.*), and Omicron (B.1.1.519 and BA.*), as well as identify samples which cannot be categorized
200 into a known VOC or VOI. Because the first part of this approach, Reaction 1, has been previously
201 described, this current study focuses on Reaction 2 and the integrated results of the two-reaction test (26).
202 Overall, these reactions showed high concordance with WGS, demonstrating over 95% PPA and NPA for
203 all targeted mutations.

204

205 Several groups have previously described similar approaches to SARS-CoV-2 variant determination by
206 RT-qPCR and digital droplet RT-PCR, particularly for the spike del69-70, E484K, and N501Y positions
207 (30-37). Some of these assays included additional mutation sites that were not in our study, such as spike
208 del144 or ORF1a Δ 3675–3677 (30, 36). These earlier assays, published prior to the rise of Delta,
209 primarily targeted VOCs Alpha, Beta, and Gamma. This was then followed by a surge of reports on the
210 detection of the Delta variant. Garson et al. utilized double-mismatch allele-specific RT-PCR at L452R
211 and T478K to differentiate Delta variant from other VOCs in 42 UK patient samples (38). Aoki et al.
212 described an approach that combines nested PCR along with high-resolution melting analysis at those
213 same mutations, which was validated in a small Japanese patient cohort (39). Barua et al. used a slightly
214 different approach, taking advantage of the difference in melting temperature of a probe targeted to Delta
215 mutation in spike T478K compared to other variants for a Delta-specific RT-FRET-PCR assay (40).
216 Another defining feature of VOC Delta is spike del156-157, which was the target of a Delta variant PCR
217 test developed by Hamill et al. (41). To our knowledge, the two-reaction multiplex RT-qPCR approach
218 outlined in this study examining six different mutation sites is the most comprehensive variant genotyping
219 test described that can identify Alpha, Beta, Gamma, Delta, and Omicron variants.

220
221 Multiplex RT-qPCR SARS-CoV-2 genotyping takes advantage of a commonly-used molecular technique
222 that can be implemented by laboratories using existing equipment, materials, and personnel. Because
223 this assay is more accessible and has a more rapid turnaround time than WGS, we envision it serving a
224 complimentary role to sequencing. The genotyping RT-qPCR can provide more detailed and up-to-date
225 epidemiological information by increasing the sample size of categorized variants in each geographic
226 region, and can be essential in tracking local outbreaks in areas without direct access to WGS. For
227 individual patients, the turnaround time of several hours also allows it to directly impact clinical care. For
228 example, VOCs show differential susceptibility to monoclonal antibody treatments, and variant reporting
229 could include this information (Supplemental Table 2) (1). Furthermore, current ongoing trials for small
230 molecule drugs and other treatments may yield more information about variant-specific treatment
231 strategies.

232
233 Importantly, RT-qPCR genotyping can help prioritize samples for sequencing. Although sequencing is
234 needed for identification of novel variants and characterization of viral evolution, pre-screening by RT-
235 qPCR can enrich for samples with atypical mutation patterns, lead to more efficient use of sequencing
236 resources, and potentially more rapid identification of new variants.

237
238 This RT-qPCR approach has several limitations as evidenced by its assay failure rate of 14% across all
239 tested samples in our initial cohort. Because multiplex RT-qPCRs involve a mixture of multiple sets of
240 primers and probes, they are inherently less sensitive than single-target assays. For samples with RNA
241 concentrations near the lower limits of detection, freeze-thaw cycles could impact RNA stability, and may
242 not yield consistent results due to stochastic variation. This issue could be alleviated by implementing a
243 Ct/RLU filter to only genotype samples most likely to yield interpretable results. Within our 1,093 sample
244 cohort, the lower assay failure rate in samples tested in our clinical virology laboratory (4%) compared to
245 near-care settings (35%) is likely attributable to genotyping only specimens with higher viral RNA levels.
246 Note, however, that even with such filtering, mutation analysis by RT-qPCR remains more sensitive than
247 WGS. The other limitation to this approach is the rapidly changing variant landscape which may render

248 such an assay obsolete in the matter of weeks. However, the inclusion of multiple targets in key residues
249 that influence viral fitness helps guard against this possibility, as evidenced by our ability to detect the
250 emergence of Omicron variant in our population. Still, flexibility and vigilance are required to re-design
251 and re-validate these types of assays as novel variants emerge.

252

253 In summary, we developed and validated a two-reaction multiplex RT-qPCR genotyping strategy that
254 interrogates six clinically relevant mutations within the SARS-CoV-2 spike: del69-70, K417N, L452R,
255 T478K, E484K, and N501Y. This approach allows for identification of WHO VOCs Alpha, Beta, Gamma,
256 Delta and Omicron with excellent concordance to WGS. Overall, this method complements WGS, and is
257 suitable for clinical decision-making, near real-time variant surveillance, and the triage of samples for
258 sequencing.

259

260 **ACKNOWLEDGEMENTS**

261 We would like to thank the Stanford Clinical Virology Laboratory Staff for their excellence and
262 perseverance in caring for our community while facing the unique challenges of this pandemic. We
263 additionally are grateful to the Stanford Protein and Nucleic Acid Facility for their synthesis of reagents on
264 short notice.
265

266 **REFERENCES**

267

- 268 1. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW.
269 2021. The biological and clinical significance of emerging SARS-CoV-2 variants. *Nat Rev Genet*
270 *22:757-773*.
- 271 2. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T,
272 Neher RA. 2018. Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* *34:4121-*
273 *4123*.
- 274 3. Day T, Gandon S, Lion S, Otto SP. 2020. On the evolutionary epidemiology of SARS-CoV-2. *Curr*
275 *Biol* *30:R849-R857*.
- 276 4. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell
277 TW, Tully DC, Washburne AD, Wenseleers T, Gimma A, Waites W, Wong KLM, van Zandvoort K,
278 Silverman JD, Group CC-W, Consortium C-GU, Diaz-Ordaz K, Keogh R, Eggo RM, Funk S, Jit M,
279 Atkins KE, Edmunds WJ. 2021. Estimated transmissibility and impact of SARS-CoV-2 lineage
280 B.1.1.7 in England. *Science* *372*.
- 281 5. Muik A, Wallisch AK, Sanger B, Swanson KA, Muhl J, Chen W, Cai H, Maurus D, Sarkar R,
282 Tureci O, Dormitzer PR, Sahin U. 2021. Neutralization of SARS-CoV-2 lineage B.1.1.7
283 pseudovirus by BNT162b2 vaccine-elicited human sera. *Science* *371:1152-1153*.
- 284 6. Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, Liu L, Kwong PD, Huang Y, Shapiro L,
285 Ho DD. 2021. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. *Cell*
286 *Host Microbe* *29:747-751 e4*.
- 287 7. Collier DA, De Marco A, Ferreira I, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D,
288 Silacci-Fregni C, Bianchi S, Tortorici MA, Bowen J, Culap K, Jaconi S, Camerini E, Snell G,
289 Pizzuto MS, Pellanda AF, Garzoni C, Riva A, Collaboration C-NBC-, Elmer A, Kingston N, Graves
290 B, McCoy LE, Smith KGC, Bradley JR, Temperton N, Ceron-Gutierrez L, Barcenas-Morales G,
291 Consortium C-GU, Harvey W, Virgin HW, Lanzavecchia A, Piccoli L, Doffinger R, Wills M, Veesler
292 D, Corti D, Gupta RK. 2021. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited
293 antibodies. *Nature* *593:136-141*.

- 294 8. Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes BF, Sanders
295 KO, Gnanakaran S, Hengartner N, Pajon R, Smith G, Dubovsky F, Glenn GM, Korber B,
296 Montefiori DC. 2021. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited
297 by ancestral Spike vaccines. bioRxiv doi:10.1101/2021.01.27.428516.
- 298 9. Karim SSA. 2021. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of
299 protection. *Lancet* 397:1263-1264.
- 300 10. Bolze A, Cirulli ET, Luo S, White S, Wyman D, Rossi AD, Machado H, Cassens T, Jacobs S,
301 Schiabor Barrett KM, Tsan K, Nguyen J, Ramirez JM, Sandoval E, Wang X, Wong D, Becker D,
302 Laurent M, Lu JT, Isaksson M, Washington NL, Lee W. 2021. SARS-CoV-2 variant Delta rapidly
303 displaced variant Alpha in the United States and led to higher viral loads. medRxiv
304 doi:10.1101/2021.06.20.21259195:2021.06.20.21259195.
- 305 11. Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett KM, Larsen BB,
306 Anderson C, White S, Cassens T, Jacobs S, Levan G, Nguyen J, Ramirez JM, Rivera-Garcia C,
307 Sandoval E, Wang X, Wong D, Spencer E, Robles-Sikisaka R, Kurzban E, Hughes LD, Deng X,
308 Wang C, Servellita V, Valentine H, De Hoff P, Seaver P, Sathe S, Gietzen K, Sickler B, Antico J,
309 Hoon K, Liu J, Harding A, Bakhtar O, Basler T, Austin B, Isaksson M, Febbo P, Becker D, Laurent
310 M, McDonald E, Yeo GW, Knight R, Laurent LC, de Feo E, Worobey M, Chiu C, Suchard MA, et
311 al. 2021. Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2
312 B.1.1.7 in the United States. medRxiv doi:10.1101/2021.02.06.21251159.
- 313 12. Chen X, Chen Z, Azman AS, Sun R, Lu W, Zheng N, Zhou J, Wu Q, Deng X, Zhao Z, Chen X, Ge
314 S, Yang J, Leung DT, Yu H. 2021. Neutralizing antibodies against SARS-CoV-2 variants induced
315 by natural infection or vaccination: a systematic review and pooled meta-analysis. *Clin Infect Dis*
316 doi:10.1093/cid/ciab646.
- 317 13. Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME,
318 Nutalai R, Tuekprakhon A, Wang B, Paesen GC, Slon-Campos J, Lopez-Camacho C, Hallis B,
319 Coombes N, Bewley KR, Charlton S, Walter TS, Barnes E, Dunachie SJ, Skelly D, Lumley SF,
320 Baker N, Shaik I, Humphries HE, Godwin K, Gent N, Sienkiewicz A, Dold C, Levin R, Dong T,
321 Pollard AJ, Knight JC, Klenerman P, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye

- 322 M, Belij-Rammerstorfer S, Gilbert S, Hall DR, Williams MA, Paterson NG, James W, Carroll MW,
323 Fry EE, Mongkolsapaya J, et al. 2021. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by
324 convalescent and vaccine sera. *Cell* 184:2201-2211 e7.
- 325 14. Hoffmann M, Arora P, Gross R, Seidel A, Hornich BF, Hahn AS, Kruger N, Graichen L, Hofmann-
326 Winkler H, Kempf A, Winkler MS, Schulz S, Jack HM, Jahrsdorfer B, Schrezenmeier H, Muller M,
327 Kleger A, Munch J, Pohlmann S. 2021. SARS-CoV-2 variants B.1.351 and P.1 escape from
328 neutralizing antibodies. *Cell* 184:2384-2393 e12.
- 329 15. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, Nutalai R, Zhou D, Mentzer
330 AJ, Zhao Y, Duyvesteyn HME, Lopez-Camacho C, Slon-Campos J, Walter TS, Skelly D, Johnson
331 SA, Ritter TG, Mason C, Costa Clemens SA, Gomes Naveca F, Nascimento V, Nascimento F,
332 Fernandes da Costa C, Resende PC, Pauvolid-Correa A, Siqueira MM, Dold C, Temperton N,
333 Dong T, Pollard AJ, Knight JC, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye M,
334 Belij-Rammerstorfer S, Gilbert SC, Malik T, Carroll MW, Klenerman P, Barnes E, Dunachie SJ,
335 Baillie V, Serafin N, Ditse Z, Da Silva K, Paterson NG, Williams MA, et al. 2021. Reduced
336 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell* 184:4220-4236
337 e13.
- 338 16. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot
339 F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani N,
340 Edriss D, Belec L, Seve A, Courtellemont L, Pere H, Hocqueloux L, Fafi-Kremer S, Prazuck T,
341 Mouquet H, Bruel T, Simon-Loriere E, Rey FA, Schwartz O. 2021. Reduced sensitivity of SARS-
342 CoV-2 variant Delta to antibody neutralization. *Nature* 596:276-280.
- 343 17. Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA, Cai H, Cutler M, Cooper D, Muik A, Jansen
344 KU, Sahin U, Xie X, Dormitzer PR, Shi PY. 2021. BNT162b2-elicited neutralization of B.1.617 and
345 other SARS-CoV-2 variants. *Nature* 596:273-275.
- 346 18. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, Dushoff J,
347 Mlisana K, Moultrie H. 2021. Increased risk of SARS-CoV-2 reinfection associated with
348 emergence of the Omicron variant in South Africa. *medRxiv*
349 doi:10.1101/2021.11.11.21266068:2021.11.11.21266068.

- 350 19. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, Metzler M, Kohmer N, Hoehl S,
351 Helfritz FA, Wolf T, Goetsch U, Ciesek S. 2021. Reduced Neutralization of SARS-CoV-2 Omicron
352 Variant by Vaccine Sera and monoclonal antibodies. medRxiv
353 doi:10.1101/2021.12.07.21267432:2021.12.07.21267432.
- 354 20. Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland WH,
355 Porrot F, Staropoli I, Lemoine F, Pere H, Veyer D, Puech J, Rodary J, Baele G, Dellicour S,
356 Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina-Bokalanga T, Marti-Carreras J,
357 Cuypers L, Seve A, Hocqueloux L, Prazuck T, Rey F, Simon-Loriere E, Bruel T, Mouquet H,
358 Andre E, Schwartz O. 2021. Considerable escape of SARS-CoV-2 Omicron to antibody
359 neutralization. Nature doi:10.1038/s41586-021-04389-z.
- 360 21. Salvatore M, Bhattacharyya R, Purkayastha S, Zimmermann L, Ray D, Hazra A, Kleinsasser M,
361 Mellan T, Whittaker C, Flaxman S, Bhatt S, Mishra S, Mukherjee B. 2021. Resurgence of SARS-
362 CoV-2 in India: Potential role of the B.1.617.2 (Delta) variant and delayed interventions. medRxiv
363 doi:10.1101/2021.06.23.21259405:2021.06.23.21259405.
- 364 22. Wang L, Cheng G. 2021. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in
365 South Africa. J Med Virol doi:10.1002/jmv.27516.
- 366 23. Zhang W, Davis BD, Chen SS, Sincuir Martinez JM, Plummer JT, Vail E. 2021. Emergence of a
367 Novel SARS-CoV-2 Variant in Southern California. JAMA 325:1324-1326.
- 368 24. Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, Scott R, Sconza R, Price J,
369 Margaritis M, Bergstrom M, Spyer MJ, Miralhes PB, Grant P, Kirk S, Valerio C, Mangera Z,
370 Prabhakar T, Moreno-Cuesta J, Arulkumaran N, Singer M, Shin GY, Sanchez E,
371 Paraskevopoulou SM, Pillay D, McKendry RA, Mirfenderesky M, Houlihan CF, Nastouli E. 2021.
372 Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in
373 London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis
374 21:1246-1256.
- 375 25. Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, Datir R, Collier DA, Albecka
376 A, Singh S, Pandey R, Brown J, Zhou J, Goonawardane N, Mishra S, Whittaker C, Mellan T,
377 Marwal R, Datta M, Sengupta S, Ponnusamy K, Radhakrishnan VS, Abdullahi A, Charles O,

- 378 Chattopadhyay P, Devi P, Caputo D, Peacock T, Wattal C, Goel N, Satwik A, Vaishya R, Agarwal
379 M, Chauhan H, Dikid T, Gogia H, Lall H, Verma K, Dhar MS, Singh MK, Soni N, Meena N, Madan
380 P, Singh P, Sharma R, Sharma R, Kabra S, Kumar S, Kumari S, Sharma U, et al. 2021. SARS-
381 CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature* 599:114-119.
- 382 26. Wang H, Miller JA, Verghese M, Sibai M, Solis D, Mfuh KO, Jiang B, Iwai N, Mar M, Huang C,
383 Yamamoto F, Sahoo MK, Zehnder J, Pinsky BA. 2021. Multiplex SARS-CoV-2 Genotyping
384 Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic
385 Surveillance. *J Clin Microbiol* 59:e0085921.
- 386 27. Sagulenko P, Puller V, Neher RA. 2018. TreeTime: Maximum-likelihood phylodynamic analysis.
387 *Virus Evol* 4:vex042.
- 388 28. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D,
389 Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen
390 JF, Group S. 2015. STARD 2015: an updated list of essential items for reporting diagnostic
391 accuracy studies. *BMJ* 351:h5527.
- 392 29. Verghese M, Jiang B, Iwai N, Mar M, Sahoo MK, Yamamoto F, Mfuh KO, Miller J, Wang H,
393 Zehnder J, Pinsky BA. 2021. A SARS-CoV-2 Variant with L452R and E484Q Neutralization
394 Resistance Mutations. *J Clin Microbiol* 59:e0074121.
- 395 30. Borsova K, Paul ED, Kovacova V, Radvanszka M, Hajdu R, Cabanova V, Slavikova M, Lickova M,
396 Lukacikova L, Belak A, Roussier L, Kosticova M, Liskova A, Madarova L, Stefkovicova M,
397 Reizigova L, Novakova E, Sabaka P, Koscalova A, Brejova B, Staronova E, Misik M, Vinar T,
398 Nosek J, Cekan P, Klempa B. 2021. Surveillance of SARS-CoV-2 lineage B.1.1.7 in Slovakia
399 using a novel, multiplexed RT-qPCR assay. *Sci Rep* 11:20494.
- 400 31. Korukluoglu G, Kolukirik M, Bayrakdar F, Ozgumus GG, Altas AB, Cosgun Y, Ketre Kolukirik CZ.
401 2021. 40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations.
402 bioRxiv doi:10.1101/2021.01.26.428302:2021.01.26.428302.
- 403 32. Perchetti GA, Zhu H, Mills MG, Shrestha L, Wagner C, Bakhsh SM, Lin MJ, Xie H, Huang ML,
404 Mathias P, Bedford T, Jerome KR, Greninger AL, Roychoudhury P. 2021. Specific allelic

- 405 discrimination of N501Y and other SARS-CoV-2 mutations by ddPCR detects B.1.1.7 lineage in
406 Washington State. *J Med Virol* 93:5931-5941.
- 407 33. Banada P, Green R, Banik S, Chopoorian A, Streck D, Jones R, Chakravorty S, Alland D. 2021.
408 A Simple Reverse Transcriptase PCR Melting-Temperature Assay To Rapidly Screen for Widely
409 Circulating SARS-CoV-2 Variants. *J Clin Microbiol* 59:e0084521.
- 410 34. Bal A, Destras G, Gaymard A, Stefic K, Marlet J, Eymieux S, Regue H, Semanas Q, d'Aubarede
411 C, Billaud G, Laurent F, Gonzalez C, Mekki Y, Valette M, Bouscambert M, Gaudy-Graffin C, Lina
412 B, Morfin F, Josset L, Group CO-DHS. 2021. Two-step strategy for the identification of SARS-
413 CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France,
414 August to December 2020. *Euro Surveill* 26.
- 415 35. Neopane P, Nypaver J, Shrestha R, Beqaj SS. 2021. SARS-CoV-2 Variants Detection Using
416 TaqMan SARS-CoV-2 Mutation Panel Molecular Genotyping Assays. *Infect Drug Resist* 14:4471-
417 4479.
- 418 36. Vogels CBF, Breban MI, Ott IM, Alpert T, Petrone ME, Watkins AE, Kalinich CC, Earnest R,
419 Rothman JE, Goes de Jesus J, Morales Claro I, Magalhaes Ferreira G, Crispim MAE, Brazil
420 UKCGN, Singh L, Tegally H, Anyaneji UJ, Network for Genomic Surveillance in South A, Hodcroft
421 EB, Mason CE, Khullar G, Metti J, Dudley JT, MacKay MJ, Nash M, Wang J, Liu C, Hui P,
422 Murphy S, Neal C, Laszlo E, Landry ML, Muyombwe A, Downing R, Razeq J, de Oliveira T, Faria
423 NR, Sabino EC, Neher RA, Fauver JR, Grubaugh ND. 2021. Multiplex qPCR discriminates
424 variants of concern to enhance global surveillance of SARS-CoV-2. *PLoS Biol* 19:e3001236.
- 425 37. Hale R, Crowley P, Dervisevic S, Coupland L, Cliff PR, Ebie S, Snell LB, Paul J, Williams C,
426 Randell P, Pond M, Stanley K. 2021. Development of a Multiplex Tandem PCR (MT-PCR) Assay
427 for the Detection of Emerging SARS-CoV-2 Variants. *Viruses* 13.
- 428 38. Garson JA, Badru S, Parker E, Tedder RS, McClure MO. 2022. Highly sensitive and specific
429 detection of the SARS-CoV-2 Delta variant by double-mismatch allele-specific real time reverse
430 transcription PCR. *J Clin Virol* 146:105049.

- 431 39. Aoki A, Adachi H, Mori Y, Ito M, Sato K, Okuda K, Sakakibara T, Okamoto Y, Jinno H. 2021. A
432 rapid screening assay for L452R and T478K spike mutations in SARS-CoV-2 Delta variant using
433 high-resolution melting analysis. *J Toxicol Sci* 46:471-476.
- 434 40. Barua S, Hoque M, Kelly PJ, Bai J, Hanzlicek G, Noll L, Walz H, Johnson C, Kyriakis C, Wang C.
435 2021. High-resolution melting curve FRET-PCR rapidly identifies SARS-CoV-2 mutations. *J Med*
436 *Viro* 93:5588-5593.
- 437 41. Hamill V, Noll L, Lu N, Tsui WNT, Porter EP, Gray M, Sebhatu T, Goerl K, Brown S, Palinski R,
438 Thomason S, Almes K, Retallick J, Bai J. 2021. Molecular detection of SARS-CoV-2 strains and
439 differentiation of Delta variant strains. *Transbound Emerg Dis* doi:10.1111/tbed.14443.
- 440
- 441

442 **FIGURE LEGENDS**

443

444 **Figure 1.** Summary of current World Health Organization (WHO)-designated variants of concern (VOC)
445 along with their expected spike mutations at sites targeted by this two-reaction multiplex SARS-CoV-2
446 RT-qPCR genotyping approach. These reactions are designed to detect the following mutations: del69-70,
447 K417N, L452R, T478K, E484K, and N501Y. Shading indicates predicted versus empiric performance of
448 this assay for the detection and differentiation of these VOCs. While the del69-70, T478K, and N501Y
449 mutations were all predicted to be not-detected by this assay in samples from Omicron-infected
450 individuals due to known adjacent mutations in the probe binding site (A67V, S477N, Q498R), del69-70
451 was detected empirically with diminished efficiency. An asterisk denotes a known limitation of the assay in
452 differentiating VOCs Beta and Gamma from the variant of interest Mu.

453

454 **Figure 2.** Nextclade phylogenetic tree of 3,097 SARS-CoV-2 genomes, including all 732 of the
455 sequenced genomes from this study, and 2,365 genomes from the Nextstrain global reference tree as of
456 February 2, 2022. The 732 included genomes are colored by RT-qPCR genotyping predicted variant type,
457 with each circle representing a sequenced genome. Branch length corresponds to nucleotide divergence.
458 Sequenced genomes span the breadth of the reference tree. Annotation to the right of the tree
459 demonstrates the variant type based on whole-genome sequencing (WGS). Variant determination by RT-
460 qPCR matched WGS except for 1 sequence typed as Beta, and 4 sequences typed as Gamma by RT-
461 qPCR which clustered with variant of interest Mu by WGS.

462

463 **TABLES**

464

465 **Table 1.** Reaction 2 Primer and Probe Oligonucleotide Sequences

466

	Name	Sequence (5' → 3')	Final Concentration
Primers	del69-70_FWD	CATTAAATGGTAGGACAGGGTTA	300 nM
	del69-70_REV	ACATTCAACTCAGGACTTGTT	300 nM
	K417N_FWD	GCAGCCTGTAATAATCATCTG	300 nM
	K417N_REV	CATTTGTAATTAGAGGTGATGAAGTC	300 nM
	T478K_FWD	AAAGGAAAGTAACAATTAACCT	300 nM
	T478K_REV	AGGAAGTCTAATCTCAAACCT	300 nM
Probes	del69-70_MT_HEX	HEX-CCTAAACAATCTATACCGGTAATT-BHQ1	50 nM
	wt69-70_WT_CY3.5 ^a	CY3.5-GGTCCCAGAGACATGTATAG-BHQ2	50 nM
	K417N_MT_CY5	CY5-TAATCAGCAATATTTCCAGT-BHQ2	50 nM
	T478K_MT_FAM	FAM-ACCATTACAAGGTTTGCTAC-BHQ1	50 nM

467 FWD, forward; REV, reverse; WT, wild-type; MT, mutant; HEX, hexachlorofluorescein; CY3.5, cyanine 3.5; CY5,
 468 cyanine 5; FAM, 5(6)-carboxyfluorescein; BHQ, Black hole quencher

469 ^a Included as an internal amplification control for samples without the del69-70 mutation

470

471 **Table 2.** Comparison of RT-qPCR and WGS Results for SARS-CoV-2 Spike Gene Mutation Detection in
 472 the Initial Cohort (n=502)
 473

Spike Mutations		WGS pos	WGS neg	PPA (95% CI)	NPA (95% CI)
Del69-70	RT-qPCR pos	43	0	100% (92-100%)	100% (99-100%)
	RT-qPCR neg	0	459		
K417N	RT-qPCR pos	27	0	96% (82-100%)	100% (99-100%)
	RT-qPCR neg	1 ^a	474		
L452R	RT-qPCR pos	403	5 ^b	100% (99-100%)	95% (89-98%)
	RT-qPCR neg	0	94		
T478K	RT-qPCR pos	379	0	100% (99-100%)	100% (97-100%)
	RT-qPCR neg	0	123		
E484K	RT-qPCR pos	35	3 ^c	100% (90-100%)	99% (98-100%)
	RT-qPCR neg	0	464		
N501Y	RT-qPCR pos	70	0	100% (95-100%)	100% (99-100%)
	RT-qPCR neg	0	432		

RT-qPCR, reverse transcription quantitative polymerase chain reaction; WGS, whole-genome sequencing; PPA, positive percent agreement; NPA, negative percent agreement; CI, confidence interval

^a False negative RT-qPCR result due to synonymous mutation in spike gene amino acid position 418 (codon ATT -> ATC) causing probe dropout.

^b False negative WGS results due to insufficient read count (<12) at this codon. Manual review of sequences revealed 3-9 mutant reads in each sample.

^c These three samples were found on WGS to be positive for E484Q. While positive for the E484K target on RT-qPCR, these samples had a distinct blunted amplification curve associated with E484Q as previously described (29).

474

475 **Table 3.** Comparison of RT-qPCR and WGS for SARS-CoV-2 Variant of Concern Detection (n=732)
476

WGS		RT-qPCR						
WHO VOC	PANGO lineage	Alpha	Beta	Gamma	Delta	Omicron	Not a VOC	All
Alpha	All Alpha	43	-	-	-	-	-	43
	B.1.1.7	37	-	-	-	-	-	37
	Q.3	6	-	-	-	-	-	6
Beta	Beta	-	2	-	-	-	-	2
	B.1.351	-	2	-	-	-	-	2
Gamma	All Gamma	-	-	20	-	-	-	20
	P.1	-	-	13	-	-	-	13
	P.1.10	-	-	5	-	-	-	5
	P.1.17	-	-	2	-	-	-	2
Delta	All Delta	-	-	-	378	-	-	378
	B.1.617.2	-	-	-	29	-	-	29
	AY.1	-	-	-	20	-	-	20
	AY.2	-	-	-	5	-	-	5
	AY.3	-	-	-	5	-	-	5
	AY.4	-	-	-	1	-	-	1
	AY.13	-	-	-	32	-	-	32
	AY.14	-	-	-	59	-	-	59
	AY.19	-	-	-	1	-	-	1
	AY.20	-	-	-	5	-	-	5
	AY.23	-	-	-	1	-	-	1
	AY.25	-	-	-	7	-	-	7
	AY.25.1	-	-	-	25	-	-	25
	AY.26	-	-	-	15	-	-	15
	AY.35	-	-	-	2	-	-	2
	AY.43	-	-	-	2	-	-	2
	AY.44	-	-	-	77	-	-	77
	AY.46.2	-	-	-	1	-	-	1
	AY.47	-	-	-	8	-	-	8
	AY.48	-	-	-	1	-	-	1
	AY.52	-	-	-	1	-	-	1
	AY.54	-	-	-	3	-	-	3
	AY.59	-	-	-	1	-	-	1
	AY.62	-	-	-	1	-	-	1
	AY.67	-	-	-	3	-	-	3
	AY.74	-	-	-	1	-	-	1
	AY.75	-	-	-	10	-	-	10
	AY.98.1	-	-	-	1	-	-	1
	AY.100	-	-	-	3	-	-	3
	AY.103	-	-	-	26	-	-	26
	AY.110	-	-	-	9	-	-	9
	AY.114	-	-	-	1	-	-	1
AY.116.1	-	-	-	2	-	-	2	
AY.118	-	-	-	5	-	-	5	
AY.119	-	-	-	4	-	-	4	
AY.120.1	-	-	-	1	-	-	1	
AY.121	-	-	-	3	-	-	3	
AY.122	-	-	-	5	-	-	5	
AY.126	-	-	-	2	-	-	2	
Omicron	All Omicron	-	-	-	-	230	-	230
	BA.1	-	-	-	-	123	-	123
	BA.1.1	-	-	-	-	107	-	107
Not a VOC	All Non- VOC	-	1	4	-	-	54	59

A.2.5	-	-	-	-	-	6	6	
B.1	-	-	-	-	-	3	3	
B.1.1.318	-	-	-	-	-	1	1	
B.1.1.519	-	-	-	-	-	1	1	
B.1.311	-	-	-	-	-	1	1	
B.1.427	-	-	-	-	-	3	3	
B.1.429	-	-	-	-	-	8	8	
B.1.526	-	-	-	-	-	10	10	
B.1.621 ^a	-	1	2	-	-	-	3	
BB.2 ^a	-	-	2	-	-	-	2	
B.1.627	-	-	-	-	-	1	1	
B.1.637	-	-	-	-	-	11	11	
XB	-	-	-	-	-	9	9	
All	All Variants	43	3	24	378	230	54	732




WGS, whole-genome sequencing; RT-qPCR, reverse transcription quantitative polymerase chain reaction; WHO, World Health Organization; VOC, variant of concern

^a Variant of interest Mu with E484K and N501Y mutations, and a subset with K417N, which overlaps with VOCs Beta and Gamma

477

Spike Protein Amino Acid Position

WHO VOC	69-70	K417	L452	T478	E484	N501
Alpha	deletion	K	L	T	E	Y
Beta*	WT	N	L	T	K	Y
Gamma*	WT	T	L	T	K	Y
Delta	WT	K	R	K	E	N
Omicron	deletion	N	L	K	A	Y

-  Mutation is predicted to be detected & is empirically detected in this variant
-  Mutation is predicted to be not detected & is empirically not detected in this variant
-  Mutation is predicted to be not detected but can be empirically detected in this variant

